• PRS43 - COST-EFFECTIVENESS OF DOXYCYCLINE VERSUS PLACEBO IN OUTPATIENT-TREATED ACUTE EXACERBATIONS OF COPD- A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PND125 - THE ASSOCIATION BETWEEN UTILITIES AND DISEASE SEVERITY FOR PARKINSON’S DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCV3 - IMPROVING ASPIRIN TOXICITY THROUGH PRECISION MEDICINE

    Oct 1, 2018, 00:00

  • PSY189 - TREATMENT GUIDELINE INCLUDING THE HEALTH ECONOMIC EVALUATIONS OF BIOLOGIC DRUGS USED FOR PSORIATIC ARTHRITIS- PICOSTEPS, SYSTEMATIC LITERATURE REVIEW, APPLICABILITY EVALUATION AND LEVEL OF EVIDENCE EVALUATION

    Oct 1, 2018, 00:00

  • PMU122 - PATIENT-REPORTED OUTCOMES ON PERCEIVED WELL-BEING AMONG PATIENTS ON ANTI-INFLAMMATORY TREATMENT

    Oct 1, 2018, 00:00

  • PUK1 - DR RAJA AHSAN AFTAB

    Oct 1, 2018, 00:00

  • PIN82 - IN SMALL DOSES- MISSING THE BOOSTER DOSE IN A REDUCED PNEUMOCOCCAL CONJUGATE VACCINATION SCHEDULE

    Oct 1, 2018, 00:00

  • PMS110 - RESEARCH APPLICATIONS OF PATIENT REPORTED OUTCOME MEASURES IN AN ACADEMIC ORTHOPAEDIC SURGERY DEPARTMENT

    Oct 1, 2018, 00:00

  • PMD167 - HEALTH TECHNOLOGY ASSESSMENT OF MOBILE HEALTH APPLICATIONS- SLOW PROGRESS IN A FAST-PACED INDUSTRY?

    Oct 1, 2018, 00:00

  • PRM180 - COMPARING QALYS GENERATED FOR THE EQ-5D-3L AND EQ-5D-5L IN A LONGITUDINAL STUDY OF CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PGI48 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) HAVE WORSE HEALTH RELATED QUALITY OF LIFE (HRQOL) THAN MATCHED CONTROLS- RESULTS FROM THE 2016 EU5 NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)

    Oct 1, 2018, 00:00

  • PIN116 - PRIORITIZING INVESTMENTS IN NEW VACCINES AGAINST EPIDEMIC INFECTIOUS DISEASES- A MULTI-CRITERIA DECISION ANALYSIS

    Oct 1, 2018, 00:00

  • PCN387 - COMPARISON OF EQ-5D-5L AND 15D INSTRUMENTS IN ASSESSING HEALTH-RELATED QUALITY OF LIFE IN BREAST CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PHP342 - HOW TO MAXIMIZE THE EX-FACTORY PRICE IN PORTUGAL, WITH SIMULTANEOUS BENEFITS FOR PATIENTS AND PAYERS – AN INDUSTRY PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM11 - A CASE STUDY OF THE IMPACT OF CEESP REVIEWS ON HAS DECISIONS

    Oct 1, 2018, 00:00

  • PDB106 - ASSESSING THE HEALTH AND ECONOMIC IMPACT OF PHARMACEUTICAL CARE IN ELDERLY PATIENTS WITH DIABETES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN138 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER IN ENGLAND

    Oct 1, 2018, 00:00

  • PUK29 - RENAL SEVERITY IN PATIENTS WITH LUPUS NEPHRITIS AT DIAGNOSIS FOR SYSTEMIC LUPUS ERYTHEMATOSUS

    Oct 1, 2018, 00:00

  • PMH65 - PERSISTENCE WITH SELECTIVE SEROTONIN (NOREPINEPHRINE) REUPTAKE INHIBITOR THERAPY IN GERMANY

    Oct 1, 2018, 00:00

  • PMU126 - SUBJECTIVE EXPECTATIONS REGARDING FUTURE HEALTH, WELL-BEING AND HEALTHCARE COSTS IN HUNGARY

    Oct 1, 2018, 00:00

  • A Generic Model for Follicular Lymphoma- Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population–Based Observational Data

    Oct 1, 2018, 00:00

  • PHP267 - LANDSCAPE ASSESSMENT OF PROSPECTIVE REAL-WORLD EVIDENCE STUDIES IN EUROPE

    Oct 1, 2018, 00:00

  • PDB63 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC HEART FAILURE BASED ON SUBGROUP OF EMPA-REG OUTCOME IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PIH26 - PRACTICE TOWARD ANTIBIOTICS PREPARATION AMONG IRANIAN PARENTS

    Oct 1, 2018, 00:00

  • PSY27 - SPINAL MUSCULAR ATROPHY- A REVIEW OF EPIDEMIOLOGY, BURDEN AND UNMET NEEDS

    Oct 1, 2018, 00:00

  • PRM127 - ECONOMIC MODELLING CONSIDERATIONS IN RARE DISEASES- A TARGETED REVIEW OF HIGHLY SPECIALISED TECHNOLOGY APPRAISALS

    Oct 1, 2018, 00:00

  • PHP238 - CARER DISUTILITY- IS IT ACCURATELY CAPTURED IN NICE APPRAISALS?

    Oct 1, 2018, 00:00

  • PMU4 - THE SAFETY OF SWITCHING BETWEEN REFERENCE BIOPHARMACEUTICALS AND BIOSIMILARS- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PCN341 - ESTIMATION OF UTILITIES ON SKELETAL-RELATED EVENTS (SRE) IN PATIENTS WITH BONE METASTATIC CANCER IN KOREA

    Oct 1, 2018, 00:00

  • PRS83 - PATIENT PERSPECTIVE ON MEDICATION ADHERENCE IN ASTHMA- A SYSTEMATIC REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • PSY106 - COST-EFFECTIVENESS OF RARE DISEASES IN SPAIN

    Oct 1, 2018, 00:00

  • PHP258 - DEVELOPMENT OF A REAL WORLD EVIDENCE STUDY DESIGN TOOL

    Oct 1, 2018, 00:00

  • PRS29 - COST ANALYSIS OF AN ERROR TARGETED INTERVENTION TO REDUCE OR ERADICATE INHALER ERRORS IN ASTHMA PATIENTS IN THE UK

    Oct 1, 2018, 00:00

  • PSS57 - TREATMENT OF ATOPIC DERMATITIS IN PORTUGAL- INSIGHTS FROM A PHYSICIANS’ SURVEY

    Oct 1, 2018, 00:00

  • PCN350 - EVALUATION OF DISEASE-SPECIFIC SKIN SYMPTOM ITEMS ON SKINDEX-29 IN CUTANEOUS T-CELL LYMPHOMA PATIENTS TREATED WITH MOGAMULIZUMAB OR VORINOSTAT

    Oct 1, 2018, 00:00

  • PMS49 - COST-EFFECTIVENESS OF FRACTURE PREVENTION PROVIDED TO ELDERLY LIVING IN THE COMMUNITY

    Oct 1, 2018, 00:00

  • PMH24 - COST IMPLICATIONS OF ANTIPSYCHOTICS DRUGS- A HOSPITAL BUDGET IMPACT MODEL

    Oct 1, 2018, 00:00

  • PMD32 - HOW CHANGES IN ELECTROCARDIOGRAPHY MONITORING AND REIMBURSEMENT PRACTICES COULD IMPACT ON SURGICAL SITE INFECTIONS AFTER CORONARY ARTERY BYPASS GRAFT SURGERY

    Oct 1, 2018, 00:00

  • PCN28 - A REVIEW OF THE EFFECTIVENESS OF PHOTODYNAMIC THERAPY FOR CANCER

    Oct 1, 2018, 00:00

  • PRM240 - ESTIMATION OF QUALITY-ADJUSTED LIFE EXPECTANCY OF ORAL CANCER PATIENTS- INTEGRATION OF LIFETIME SURVIVAL ADJUSTED WITH REPEATED QUALITY OF LIFE MEASUREMENTS

    Oct 1, 2018, 00:00

  • PSS66 - IDENTIFYING THE MOST SUITABLE QUALITY OF LIFE ASSESSMENT TOOLS TO MEASURE HUMANISTIC BURDEN OF ACUTE OTITIS MEDIA IN CHILDREN

    Oct 1, 2018, 00:00

  • PMD178 - GLOBAL BURDEN OF PRESBYOPIA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCP18 - EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT- A MARKER OF HTA FAILURE?

    Oct 1, 2018, 00:00

  • PMD20 - COMPARATIVE STUDY OF SPINE ANTERIOR LUMBAR INTERBODY FUSION DEVICES

    Oct 1, 2018, 00:00

  • PCP50 - PERFORMANCE INDICATORS IN THE MONITORING OF OUTSOURCED PUBLIC HEALTH SERVICES

    Oct 1, 2018, 00:00

  • PMD23 - EASYPOD™ CONNECT OBSERVATIONAL STUDY (ECOS) – FRENCH CASE HISTORIES AND GROWTH OUTCOMES

    Oct 1, 2018, 00:00

  • PMS3 - INFLIXIMAB FOR DISEASE-MODIFYING ANTI-RHEUMATIC DRUG-NAIVE RHEUMATOID ARTHRITIS PATIENTS- SYSTEMATIC REVIEW AND DESCRIPTIVE ANALYSIS OF PUBLICATIONS OF RANDOMIZED CONTROLLED TRIALS

    Oct 1, 2018, 00:00

  • PCV146 - SYSTEMATIC LITERATURE REVIEW OF UTILITY DECREMENTS ASSOCIATED WITH THE NON-FATAL MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)

    Oct 1, 2018, 00:00

  • PCV44 - EFFECTIVENESS OF SACUBITRIL/VALSARTAN VERSUS ENALAPRIL IN REDUCING MORTALITY AND HOSPITALIZATIONS COSTS FROM A MOROCCAN HOSPITAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PMD126 - DO OUTCOMES DIFFER BY THE TYPE OF ACUTE ISCHEMIC DIAGNOSIS? A RETROSPECTIVE ANALYSIS OF US HOSPITAL DATABASE

    Oct 1, 2018, 00:00

  • PMD114 - ASSESSING AND MODELING ORGANIZATIONAL IMPACT OF TILMANOCEPT IN PERFORMING SENTINEL LYMPH NODE BIOPSY IN FRANCE

    Oct 1, 2018, 00:00

  • PSY63 - COST BY OUTCOMES ANALYSIS OF NOVEL TRIPLE-COMBINATION THERAPIES FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN BRAZIL

    Oct 1, 2018, 00:00

  • PRS45 - COST-EFFECTIVENESS OF BEDAQUILINE VERSUS INJECTABLE STANDARD-OF-CARE AGENTS FOR THE TREATMENT OF DRUG-RESISTANT TUBERCULOSIS (DR-TB) IN RUSSIA, INDIA, AND SOUTH AFRICA- BREAKTHROUGH INNOVATION DRIVING DOWN COST OF TREATMENT SUCCESS

    Oct 1, 2018, 00:00

  • PCN131 - ASSESSING THE REAL-WORLD COST OF CARE IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC) IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PSY215 - MEASURING QUALITY OF LIFE FOR ECONOMIC EVALUATION IN DUCHENNE MUSCULAR DYSTROPHY (DMD) FROM CHILDHOOD TO ADULTHOOD- PROTOCOL FOR A NEW PREFERENCE-BASED MEASURE

    Oct 1, 2018, 00:00

  • PRM113 - PREDICTION MODEL FOR IDENTIFYING PATIENTS WITH LIPODYSTROPHY IN ELECTRONIC HEALTH RECORDS

    Oct 1, 2018, 00:00

  • PIN53 - IS THE RECOMBINANT ZOSTER VACCINE ALSO COST-EFFECTIVE FOR THE GERMAN POPULATION ≥50 YEARS OF AGE?

    Oct 1, 2018, 00:00

  • PMU26 - BUDGET IMPACT ANALYSIS OF INTRAVENOUS BIOSIMILARS COMPARED WITH INTRAVENOUS ORIGINATORS AND SUBCUTANEOUS PRODUCTS

    Oct 1, 2018, 00:00

  • PSY103 - MODELLING AVERAGE COST AND COST-PER-RESPONDER FOR BIOLOGICAL TREATMENTS FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS WITH DOSE ESCALATION AND REAL-WORLD DRUG SURVIVAL

    Oct 1, 2018, 00:00

  • PCN151 - COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB IN THE TREATMENT OF PATIENTS WITH HEPATOCELULLAR CARCINOMA PREVIOUSLY TREATED WITH SORAFENIB IN PORTUGAL

    Oct 1, 2018, 00:00

  • PDB11 - CHART REVIEW ANALYSIS OF INSULIN GLARGINE 300 AND INSULIN GLARGINE 100 USE IN FRANCE, SPAIN, AND GERMANY

    Oct 1, 2018, 00:00

  • PSY178 - FACTORS ASSOCIATED WITH OBESITY IN GREECE

    Oct 1, 2018, 00:00

  • PIN67 - COST-EFFECTIVENESS OF QUADRIVALENT INFLUENZA VACCINATION IN GERMANY

    Oct 1, 2018, 00:00

  • PMD27 - LENS EXPLANTATION AND LENS EXCHANGE RATES WITH MULTIFOCAL IOLS- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PGI50 - HAPPY TOMORROW BUT GLOOMING ELDERLY? SELF-ESTIMATION OF FUTURE HEALTH IN CROHN’S DISEASE

    Oct 1, 2018, 00:00

  • PCN370 - COMPARISONS ON THE CHANGE OF PSYCHOSOCIAL ILLNESS IMPACT ACROSS FOUR CANCER SURVIVORS

    Oct 1, 2018, 00:00

  • PMD101 - COST-EFFECTIVENESS OF TRANSFEMORAL TRANSCATHETER AORTIC VALVE REPLACEMENT VERSUS SURGICAL AORTIC VALVE REPLACEMENT IN INTERMEDIATE-LOW RISK PATIENTS WITH SEVERE AORTIC STENOSIS IN SINGAPORE

    Oct 1, 2018, 00:00

  • PCN78 - EVALUATING THE ECONOMIC CONSEQUENCES OF NOVEL AGENTS FOR TREATING HODGKIN LYMPHOMA IN GREECE

    Oct 1, 2018, 00:00

  • PHP194 - THE EMA CLINICAL DATA WEBSITE- A CONCEPTUAL EXPLORATORY APPROACH TO BENCHMARK CLINICAL DEVELOPMENT INDICATORS IN MARKETING AUTHORIZATIONS

    Oct 1, 2018, 00:00

  • PMU96 - DUTCH HEALTH STATE UTILITIES FOR INFERTILITY AND SUBFERTILITY

    Oct 1, 2018, 00:00

  • PCV57 - HEALTH INSURANCE COST OF HYPERTENSIVE HEART DISEASE IN HUNGARY- A NATIONWIDE COST OF ILLNESS STUDY

    Oct 1, 2018, 00:00

  • PCN340 - REAL-WORLD USAGE OF BORTEZOMIB IN COMBINATION WITH MELPHALAN AND PREDNISONE (VMP) AS FRONTLINE (FL) TREATMENT IN STEM CELL TRANSPLANT (SCT) INELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ACROSS EU5 COUNTRIES

    Oct 1, 2018, 00:00

  • PDB82 - RE-ANALYSIS OF THE DIABETES PREVENTION PROGRAM (DPP) 3 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) USING IDENTICAL DATA BUT PROPER QALY CALCULATIONS MAY REVIVE ITS METFORMIN CONCLUSIONS

    Oct 1, 2018, 00:00

  • PND129 - SATISFACTION AND EXPERIENCES OF PATIENTS TAKING FINGOLIMOD AND INVOLVED IN A PHARMACY-BASED PATIENT SUPPORT PROGRAM – SATFINO QUALITATIVE STUDY

    Oct 1, 2018, 00:00

  • PSS2 - VALIDATION STUDY OF AN INFANTILE HEMANGIOMA (IH) SCORING TOOL FOR PRIMARY CLINICIANS TO IDENTIFY PATIENTS REQUIRING REFERRAL TO EXPERT CENTERS

    Oct 1, 2018, 00:00

  • PSY192 - PATIENT HEALTH-RELATED QUALITY OF LIFE ASSOCIATED WITH REMISSION OF ATTP, A REGRESSION ANALYSIS USING NON-RANDOMISED OBSERVATIONAL DATA FROM THE OKLAHOMA TTP REGISTRY

    Oct 1, 2018, 00:00

  • PCN331 - PERTUZUMAB RISK SHARING AGREEMENT IN THE PORTUGUESE NHS

    Oct 1, 2018, 00:00

  • PRS24 - INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) - SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS FF/VI AND UMEC/VI IN PATIENTS WITH COPD- HEALTHCARE RESOURCE UTILIZATION DATA AND ASSOCIATED COSTS – GERMANY

    Oct 1, 2018, 00:00

  • PRM23 - MODELLING CANCER TREATMENTS IN THE ADJUVANT SETTING- A TARGETED LITERATURE REVIEW (TLR) OF TECHNOLOGY APPRAISALS (TA) OF ADJUVANT THERAPIES SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) AND A CASE STUDY I ...

    Oct 1, 2018, 00:00

  • PCV52 - COST COMPARISON- STRATEGIES OF PATIENTS MANAGEMENT IN ORAL ANTICOAGULANT THERAPY

    Oct 1, 2018, 00:00

  • PDB89 - THE BURDEN OF PREGNANCY HYPERGLYCEMIA IN INDONESIAN WOMEN

    Oct 1, 2018, 00:00

  • PMS5 - A NETWORK META-ANALYSIS TO EVALUATE THE EFFICACY OF BARICITINIB AND OTHER TREATMENTS OF RHEUMATOID ARTHRITIS IN PATIENTS WHO ARE INADEQUATE RESPONDERS TO METHOTREXATE

    Oct 1, 2018, 00:00

  • PHP157 - APETITE FOR ON PATENTS- COST OF PRESCRIBING SWITCHING IN GREECE

    Oct 1, 2018, 00:00

  • PHP325 - ORPHAN DRUGS‘ MARKET ACCESS CHALLENGES IN EUROPE FROM A GERMAN PERSPECTIVE

    Oct 1, 2018, 00:00

  • PHP46 - IS EUROPE WAKING UP TO BIOPHARMACEUTICAL INNOVATION? PERSPECTIVES FROM EXPERT APPRAISAL OF RECENT ORPHAN DISEASE THERAPY VALUE ASSESSMENTS AND THEIR SUPPORTING LEGAL / POLICY FRAMEWORKS

    Oct 1, 2018, 00:00

  • PRM66 - AN EXPLORATION OF THE METHODOLOGY FOR CONSIDERING TREATMENT DURATION IN BUDGET IMPACT ANALYSES IN ONCOLOGY- A CASE STUDY IN SECOND LINE ADVANCED RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PSY13 - THE TREATMENT OPTIONS FOR ACUTE ATTACK OF HEREDITARY ANGIOEDEMA (HAE)- A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PND60 - COST-EFFECTIVENESS OF TERIFLUNOMIDE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN GREECE

    Oct 1, 2018, 00:00

  • PDB91 - EXPLAINING THE DISPARITIES OF MARKET ACCESS FOR GLIFLOZINS IN FRANCE, SPAIN, GERMANY AND THE UNITED-KINGDOM

    Oct 1, 2018, 00:00

  • PCV5 - REAL-WORLD LDL-C CHANGES EXPERIENCED WITH LOMITAPIDE MODELLED TO POTENTIALLY INCREASE LIFE-EXPECTANCY IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)

    Oct 1, 2018, 00:00

  • PMS103 - IMPACT OF PHYSICAL FUNCTIONING ON THE QUALITY OF LIFE AFTER TOTAL KNEE REPLACEMENT

    Oct 1, 2018, 00:00

  • PND29 - LONG RANGE SIMULATION OF THE COST BURDEN OF DIFFERENCE TREATMENT SEQUENCES APPROVED FOR THE TREATMENT OF HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PSY196 - THE ECONOMIC BURDEN AND IMPACT ON QUALITY OF LIFE OF HERPES ZOSTER AND POSTHERPETIC NEURALGIA IN INDIVIDUALS AGED 50 YEARS OR OLDER IN ITALY

    Oct 1, 2018, 00:00

  • PHP200 - A REVIEW OF ACHIEVEMENTS AND CHALLENGES OF IRAN’S HEALTH TRANSFORMATION PLAN

    Oct 1, 2018, 00:00

  • PIN55 - COST-EFFECTIVENESS ANALYSIS OF INFANT FORMULA SUPPLEMENTED WITH HUMAN MILK OLIGOSACCHARIDE (HMO) IN THE PREVENTION OF LOWER RESPIRATORY TRACT INFECTIONS IN MEXICO AND CHINA

    Oct 1, 2018, 00:00

  • PMH1 - PATIENT-REPORTED SIDE EFFECTS OF BUPRENORPHINE-NALOXONE- IDENTIFYING INDEPENDENT PREDICTORS FROM PATIENT VIEWS AND CLINICAL ASSESSMENT DURING MAINTENANCE TREATMENT OF HEROIN USE DISORDER

    Oct 1, 2018, 00:00

  • PSY144 - DRUGS INVOLVED IN LAWSUITS FILED AGAINST THE UNIFIED HEALTH SYSTEM (SUS) IN SÃO PAULO - BRAZIL, IN 2017

    Oct 1, 2018, 00:00

  • PCV37 - IDENTIFICATION OF FACTORS AFFECTING READMISSIONS IN HEART FAILURE PATIENTS

    Oct 1, 2018, 00:00

  • PIN13 - THE INCIDENCE OF SURGICAL SITE INFECTION IN POLAND

    Oct 1, 2018, 00:00

  • PSY32 - CLAIMS-BASED ANALYSIS OF HOMOCYSTEINE TESTING, ELEVATED HOMOCYSTEINE LEVELS, AND HOMOCYSTINURIA DIAGNOSIS IN THE U.S.

    Oct 1, 2018, 00:00

  • PMU60 - IS TRANSPARENCY IN SLOVAK HTA EFFICIENT ENOUGHT? COMPARING PHARMACOECONOMICS METHODOLOGIES USED IN PRICING REIMBURSEMENT APPLICATIONS FOR INNOVATIVE THERAPIES TOWARDS REQUIREMENTS DEFINED BY THE LAW

    Oct 1, 2018, 00:00

  • PSY218 - SYMPTOM AND IMPACT DISTURBANCE- FINDINGS FROM A QUALITATIVE ASSESSMENT OF PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

    Oct 1, 2018, 00:00

  • PRS38 - COST-CONSEQUENCE ANALYSIS OF FLUTICASONE FUROATE/VILANTEROL FOR ASTHMA MANAGEMENT IN SPAIN- AN ANALYSIS BASED ON THE SALFORD LUNG STUDY IN ASTHMA

    Oct 1, 2018, 00:00

  • PMH6 - LURASIDONE INDUCED SUICIDAL IDEATION AND HALLUCINATION- DISPROPORTIONALITY ANALYSIS IN FDA ADVERSE EVENT REPORTING SYSTEM DATABASE

    Oct 1, 2018, 00:00

  • PHP336 - THE PRESCRIPTION COST ANALYSIS AS A TOOL TO INFORM HEALTHCARE RESOURCE ALLOCATION AND ACCESS TO PHARMACEUTICALS IN ENGLAND

    Oct 1, 2018, 00:00

  • Development of a Patient-Reported Outcome Measure for Geriatric Care- The Older Persons and Informal Caregivers Survey Short Form

    Oct 1, 2018, 00:00

  • PHP141 - THE PRIVATE HEALTHCARE MARKET IN BRAZIL- A REVIEW OF 18 YEARS OF PROGRESS

    Oct 1, 2018, 00:00

  • PIN104 - MENINGOCOCCAL GROUP B (MENB) VACCINE SERIES COMPLETION AND COMPLIANCE AMONG COMMERCIALLY-INSURED INDIVIDUALS AGED 16-23 IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PIN11 - HPV9-RELATED DISEASES- THE ECONOMIC BURDEN ON THE SOCIAL SECURITY SYSTEM IN ITALY

    Oct 1, 2018, 00:00

  • PHP97 - NONADHERENCE TO TACROLIMUS IN ADULT LIVER AND KIDNEY TRANSPLANTATION IS ASSOCIATED WITH A HIGHER RISK OF EFFICACY FAILURE- REAL-WORLD EVIDENCE FROM ITALIAN ADMINISTRATIVE DATABASES

    Oct 1, 2018, 00:00

  • PMD54 - DRUG-COATED BALLOON THERAPY FOR TREATMENT OF CRITICAL LIMB ISCHEMIA IN FEMOROPOPLITEAL ARTERY DISEASE- ECONOMIC ANALYSIS FOR THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PCV36 - ESTIMATION OF THE INCREASED RISK ASSOCIATED WITH RECURRENT EVENTS OR POLY-VASCULAR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN THE UNITED KINGDOM FOR USE IN ECONOMIC EVALUATIONS

    Oct 1, 2018, 00:00

  • PHP136 - CHANGES IN THE NUMBER OF PHYSIOTHERAPIST WORKFORCE IN EUROPEAN COUNTRIES BETWEEN 2000-2015

    Oct 1, 2018, 00:00

  • PHP314 - THE RISE OF NICE ADVICE ON THE USE OF PHARMACEUTICALS, MEDICAL DEVICES AND DIGITAL HEALTH CARE IN THE NHS

    Oct 1, 2018, 00:00

  • PMH55 - A COMPARISON OF PATIENTS PRESCRIBED ANTIPSYCHOTICS FOR PARKINSON’S DISEASE WITH PSYCHOSIS USING ADMINISTRATIVE CLAIMS DATA FROM A LARGE U.S. INSURER

    Oct 1, 2018, 00:00

  • PDB37 - BUDGET IMPACT ANALYSIS OF THE ADULT TYPE 1 DIABETES MELLITUS NATIONAL CLINICAL GUIDELINE IN IRELAND

    Oct 1, 2018, 00:00

  • PMD134 - MEDICAL DEVICE APPRAISAL IN THE UK- WHAT ARE THE COMMON PITFALLS OF MANUFACTURER LITERATURE REVIEWS?

    Oct 1, 2018, 00:00

  • PHP132 - CAN BLOCKCHAIN TECHNOLOGY IMPROVE THE QUALITY OF CLINICAL TRIAL EVIDENCE? – A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP64 - ALLOWABILITY OF OUTCOMES-BASED RISK-SHARING SCHEMES IN RUSSIA WITHIN CURRENT LEGISLATIVE HURDLES

    Oct 1, 2018, 00:00

  • PMU13 - REALIZING TRANSPARENCY- REGISTRATION OF REAL-WORLD EVIDENCE STUDIES OF TREATMENT AND/OR COMPARATIVE EFFECTIVENESS

    Oct 1, 2018, 00:00

  • PRM174 - OPERATING SYSTEM UPGADES DO NOT ADVERSELY AFFECT ECOA COMPLETION BEHAVIOR WHEN USING A BRING YOUR OWN DEVICE (BYOD) APP.

    Oct 1, 2018, 00:00

  • PSY150 - INEQUITY OF ORPHAN DRUGS PRICES IN EUROPE

    Oct 1, 2018, 00:00

  • PMS19 - A BUDGET IMPACT ANALYSIS OF INTRODUCING A FORCED TREATMENT PATHWAY USING THE LOWEST PRICED ANTI-TUMOR NECROSIS FACTOR AGENT FOR RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS IN THE PHILIPPINES

    Oct 1, 2018, 00:00

  • PCP29 - BRAZILIAN PHARMACEUTICAL CLINICAL SERVICES- A DOCUMENTARY ANALYSIS

    Oct 1, 2018, 00:00

  • PCN194 - COST-EFFECTIVENESS OF SCALING-UP CERVICAL CANCER SCREENING RATES AND HPV VACCINE INITIATION IN TURKEY

    Oct 1, 2018, 00:00

  • PDB73 - INDIRECT COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN COMPARED TO CANAGLIFLOZIN FOR PATIENTS WITH T2DM AND CARDIOVASCULAR DISEASE IN THE SPANISH NATIONAL HEALTH SERVICE

    Oct 1, 2018, 00:00

  • PRS17 - BUDGET IMPACT ANALYSIS OF THE USE OF UMECLIDINIUM BROMIDE/VILANTEROL 62.5/25 MCG IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN

    Oct 1, 2018, 00:00

  • PMS53 - VALIDATION IN A REAL WORLD SCENARIO OF A CLINICAL DECISION SUPPORT SYSTEM FOR THE PREVALENCE, FRACTURE RISKS AND TREATMENT OF OSTEOPOROSIS IN THE BRAZILIAN PRIVATE MARKET

    Oct 1, 2018, 00:00

  • PCN36 - THE EFFECT OF INTRODUCING NIVOLUMAB IN THE ADJUVANT TREATMENT SETTING OF MALIGNANT MELANOMA

    Oct 1, 2018, 00:00

  • PCN362 - UNDERSTANDING PATIENT AND CLINICIAN PERCEPTIONS OF CELL AND GENE THERAPY IN ONCOLOGY USING QUALITATIVE ANALYSES OF SOCIAL MEDIA DATA

    Oct 1, 2018, 00:00

  • PMH3 - COMPARING THE RISK OF SUICIDALITY IN ADULT VERSUS YOUTH PATIENTS TREATED WITH SEROTONIN REUPTAKE INHIBITORS - A REAL-WORLD EVIDENCE-BASED APPROACH

    Oct 1, 2018, 00:00

  • PHP297 - CHANGES IN ULTRA-ORPHAN DRUG ASSESSMENTS IN POLAND

    Oct 1, 2018, 00:00

  • PSS67 - UNDERSTANDING THE PATIENT EXPERIENCE OF PRESBYOPIA AND IDENTIFICATION OF PATIENT-REPORTED OUTCOME ASSESSMENTS- A LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN224 - TOWARDS CLINICAL ADOPTION OF REPURPOSED DRUGS IN ONCOLOGY- OVERCOMING REGULATORY AND MARKET ACCESS BARRIERS IN EUROPE

    Oct 1, 2018, 00:00

  • PCN42 - EFFICACY OF THIRD LINE TYROSINE KINASE INHIBITORS FOR TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOURS- SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2018, 00:00

  • PMD15 - COMPUTER-ASSISTED (TAONET®) AND MANUAL DOSAGE CONTROL OF PATIENTS ON ORAL ANTICOAGULANT THERAPY IN ROUTINE CLINICAL PRACTICE. PRELIMINARY RESULTS OF A MULTICENTER STUDY

    Oct 1, 2018, 00:00

  • PMU63 - EFFICIENCY ASSESSMENT IN PRIMARY HEALTHCARE CENTERS OF A HEALTH DISTRICT

    Oct 1, 2018, 00:00

  • PHP169 - MCDA EVIDEM REFERENCE VALUE FRAMEWORK FOR DRUG EVALUATION AND DECISION MAKING IN SPAIN

    Oct 1, 2018, 00:00

  • PMU52 - COST IN COMPLEX ABDOMINAL OPERATIONS IN PUBLIC HEALTH INSURANCE PERSPECTIVE FOR TURKEY

    Oct 1, 2018, 00:00

  • PCN14 - COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PMU91 - USE OF EQ-5D IN CENTRAL AND EASTERN EUROPE 2000-2015- NEUROLOGICAL DISORDERS

    Oct 1, 2018, 00:00

  • PDB76 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO LIRAGLUTIDE BASED ON CARDIOVASCULAR OUTCOME TRIALS

    Oct 1, 2018, 00:00

  • PMH17 - PREDICTING RECURRENCE OF DEPRESSION USING LIFELOG DATA- A PANEL VAR APPROACH

    Oct 1, 2018, 00:00

  • PGI49 - HUMANISTIC BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) – IN THE FIRST REAL-WORLD CROSS-SECTIONAL STUDY, SYMPTOMATIC NASH PATIENTS REPORT WORSE QUALITY OF LIFE

    Oct 1, 2018, 00:00

  • PHP15 - NEW TREATMENT METHODS AND REIMBURSEMENT- EXPERIENCES IN GERMANY 2018

    Oct 1, 2018, 00:00

  • PCN156 - PHARMACOECONOMICS OF NIMOTUZUMAB IN PATIENTS WITH HEAD AND NECK CANCER IN CUBA

    Oct 1, 2018, 00:00

  • PCN105 - ECONOMIC BURDEN OF RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN FRANCE

    Oct 1, 2018, 00:00

  • PCP10 - PATIENT ACCESS TO NEW MEDICINES; THE CHANGING LANDSCAPE

    Oct 1, 2018, 00:00

  • PHP11 - HOW TO RESOLVE ISSUES EXPERIENCED BY PATIENTS IN EARLY PHASE DEVELOPMENT OF PHARMACEUTICAL PRODUCTS

    Oct 1, 2018, 00:00

  • PSY216 - THE RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE AND CLINICAL VERSUS SELF-REPORTED BODY MASS INDEX

    Oct 1, 2018, 00:00

  • PHP174 - ARE FIXED THERAPEUTIC-LEVEL SPENDING CAPS ADVISABLE FOR THE GREEK OUTPATIENT MARKET? METHODOLOGICAL ISSUES AND HEALTH POLICY PROPOSALS

    Oct 1, 2018, 00:00

  • PMD162 - AMERICAN COLLEGE OF MEDICAL GENETICS (ACMG) NEWBORN SCREENING (NBS) RECOMMENDATIONS- SENSITIVITY TO ACCOUNTING FOR REPORTED MISSING DATA IN THE CASE OF GLUTARIC ACIDURIA II (GAII)

    Oct 1, 2018, 00:00

  • PMD30 - BUDGET IMPACT ANALYSIS OF ROUTINE ADOPTION OF NON-INVASIVE PRENATAL TESTING (NIPT) IN DIFFERENT RISK-SCORE PREGNANCY POPULATIONS IN THE UK

    Oct 1, 2018, 00:00

  • PDB45 - COSTS OF PREVENTION, MONITORING AND TREATMENT OF IODINE DEFICIENCY DISORDERS IN GERMANY

    Oct 1, 2018, 00:00

  • PIH29 - DEVELOPMENT OF A DECISION AID PROTOTYPE FOR PARENTS CONSIDERING TUBE FEEDING FOR THEIR CHILDREN

    Oct 1, 2018, 00:00

  • PMS26 - COMPARATIVE TREATMENT COSTS OF SURGICAL VS NON-SURGICAL PATIENTS WITH MEDIAL MENISCUS DEFICIENCY- RESULTS FROM A 24-MONTH SURVEILLANCE STUDY

    Oct 1, 2018, 00:00

  • PND117 - PHYSICIAN REPORTED ADHERENCE IN MS PATIENTS TREATED WITH INJECTABLE PLATFORM THERAPIES VERSUS DELAYED-RELEASE DIMETHYL FUMARATE- FINDINGS FROM A REAL-WORLD CROSS-SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • PSS55 - COMPARATIVE EFFECTIVENESS OF INTEGRATED LOCAL TREATMENTS OF GENERALIZED PERIODONTITIS AND CHRONIC GINGIVITIS

    Oct 1, 2018, 00:00

  • PSY96 - COST-EFFECTIVENESS OF ORIGINATOR ADALIMUMAB IN NON-INFECTIOUS INTERMEDIATE, POSTERIOR AND PAN-UVEITIS FROM A SOCIETAL PERSPECTIVE IN PORTUGAL

    Oct 1, 2018, 00:00

  • PIN24 - ESTIMATION OF HOSPITAL COST SAVINGS ASSOCIATED WITH HYPOTENSION REDUCTION IN SEPTIC INTENSIVE CARE UNIT PATIENTS IN US HOSPITALS

    Oct 1, 2018, 00:00

  • PCP61 - EVIDENCE-BASED VALUE OF PD-1 / PD-L1 INHIBITORS IN NSCLC- COMPARISON OF VALUE TO PRICE

    Oct 1, 2018, 00:00

  • PMU5 - THE ROLE OF MULTIMORBIDITY ON EARLY RETIREMENT IN EUROPE - RESULTS FROM THE SURVEY OF HEALTH, AGEING AND RETIREMENT IN EUROPE (SHARE)

    Oct 1, 2018, 00:00

  • PRM98 - FACTORS ASSOCIATED WITH THE INCIDENCE OF ONCOLOGY DRUGS SHORTAGES IN THE UNITED STATES (2001-2017)

    Oct 1, 2018, 00:00

  • PSY10 - PATIENT CHARACTERISTICS AND IN-HOSPITAL MANAGEMENT OF EPISODES OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA- A FRENCH REAL-LIFE POPULATION BASED STUDY

    Oct 1, 2018, 00:00

  • PMD155 - IMPACT OF MINIMALLY INVASIVE TREATMENTS FOR PERIPHERAL ARTERIAL DISEASE IN HUNGARY

    Oct 1, 2018, 00:00

  • PHP345 - INNOVATIVE PAYMENT MODELS FOR BREAKTHROUGH THERAPIES

    Oct 1, 2018, 00:00

  • PND67 - ARE NEW PREVENTIVE MIGRAINE DRUGS COST-EFFECTIVE FOR PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE FOR WHOM OTHER PREVENTIVE MEDICATIONS HAD FAILED?

    Oct 1, 2018, 00:00

  • PCN18 - TREATMENT OF POST-MENOPAUSAL ADVANCED BREAST CANCER- NETWORK META-ANALYSIS USING SECOND-ORDER FRACTIONAL POLYNOMIALS MODELS

    Oct 1, 2018, 00:00

  • PCV38 - BUDGET IMPACT OF ALIROCUMAB IN THE MANAGEMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS IN ARGENTINA

    Oct 1, 2018, 00:00

  • PRM209 - HOW DO WE MEASURE UTILITIES OUTSIDE OF TRIALS IN RARE DISEASES?

    Oct 1, 2018, 00:00

  • PCN275 - HOW DO HTA DECISIONS FOR NEW DISEASE CONDITIONS IMPACT TIME TO PRICE CHANGES?

    Oct 1, 2018, 00:00

  • PHP346 - THE EVOLUTION FROM INTEREST TO EXECUTION- AN ANALYSIS OF RECENT TRENDS IN OUTCOMES BASED CONTRACTING ACROSS THE US AND EU

    Oct 1, 2018, 00:00

  • RM2 - MIXTURE METHODS INCORPORATING GENERAL POPULATION MORTALITY IN THE LIKELIHOOD FUNCTION OF PARAMETRIC DISTRIBUTIONS

    Oct 1, 2018, 00:00

  • PCN255 - CERVICAL AND BREAST CANCER IN KAZAKHSTAN BEFORE AND AFTER THE INTRODUCTION OF SCREENING- AN INTERRUPTED TIME SERIES ANALYSIS

    Oct 1, 2018, 00:00

  • PHP182 - EXTERNAL REFERENCE PRICING- CONSEQUENCES OF FRENCH PRICE DECREASES ON INTERNATIONAL TURNOVER

    Oct 1, 2018, 00:00

  • PMS52 - COST-EFFECTIVENESS ANALYSIS OF TELEREHABILITATION FOR POST-ACUTE HIP ARTHROPLASTY- A DECISION MODEL

    Oct 1, 2018, 00:00

  • PMD168 - MARKET ACCESS FOR COMPANION DIAGNOSTICS IN ONCOLOGY IN THE EU5 AND ASIA-PACIFIC REGION

    Oct 1, 2018, 00:00

  • PCN110 - COSTS ASSOCIATED WITH TRACHEA, BRONCHUS AND LUNG CANCER IN RUSSIA IN 2016 YEAR

    Oct 1, 2018, 00:00

  • PCN101 - COSTS AND HEALTHCARE RESOURCE USE ASSOCIATED WITH MAINTENANCE THERAPY IN MULTIPLE MYELOMA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PSY42 - EXPLORING THE POTENTIAL BUDGET IMPACT OF EMICIZUMAB FOR HEMOPHILIA A WITH INHIBITOR IN ITALY

    Oct 1, 2018, 00:00

  • PCN253 - DID THE EUROPEAN FINANCIAL CRISIS HAVE AN IMPACT ON ECONOMIC DECISION-MAKING IN HEALTH TECHNOLOGY ASSESSMENTS?

    Oct 1, 2018, 00:00

  • PDB66 - INSULIN GAP IN TYPE 2 DIABETES- IS IT COST EFFECTIVE TO INTENSIFY TREATMENT? EVIDENCE FROM PORTUGAL USING REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PHP37 - SPEEDING TO MARKET? AN EVALUATION OF ACCELERATED DRUG APPROVAL PATHWAYS IN AUSTRALIA, CANADA, AND SAUDI ARABIA

    Oct 1, 2018, 00:00

  • PIH27 - IRANIAN PARENTS' KNOWLEDGE ABOUT ANTIBIOTICS

    Oct 1, 2018, 00:00

  • PCN8 - SEVERITY OF BREAST CANCER ASSOCIATED WITH TYPE 2 DIABETES AND NOT WITH INSULIN TREATMENT

    Oct 1, 2018, 00:00

  • PHP180 - ACCESS AND VALUE OF HEALTHCARE INNOVATION IN LATIN AMERICA

    Oct 1, 2018, 00:00

  • PDB123 - WHAT ARE THE MOST VALUED PATIENT OUTCOMES REGARDING MEDICAL CARE FOR FRENCH PATIENTS WITH TYPE 1 DIABETES? RESULTS FROM AN ONLINE PATIENT COMMUNITY (CARENITY.COM)

    Oct 1, 2018, 00:00

  • PCN145 - COST-EFFECTIVENESS OF NINTEDANIB FOR THE TREATMENT OF NON-SMALL LUNG CANCER IN PORTUGAL

    Oct 1, 2018, 00:00

  • PDB60 - COST-CONSEQUENCE ANALYSIS FOR RECOMBINANT HUMAN GROWTH HORMONE TREATMENT ADMINISTERED VIA DIFFERENT DEVICES IN CHILDREN WITH GROWTH HORMONE DEFICIENCY IN ITALY

    Oct 1, 2018, 00:00

  • PCP23 - DOES THE EUROPEAN UNION (EU) NEED EUROPEAN HTA OR EUROPEAN PROCUREMENT?

    Oct 1, 2018, 00:00

  • PIN42 - DETERMINATING THE ACCEPTABLE PRICE FOR QUADRIVALENT INFLUENZA VACCINE IN RUSSIA

    Oct 1, 2018, 00:00

  • PCN228 - REAL-WORLD USE OF PEMBROLIZUMAB AND NIVOLUMAB FROM CLINICAL TRIALS TO MARKET LAUNCH- WHAT CAN BE LEARNED?

    Oct 1, 2018, 00:00

  • PSY139 - CURRENT USE OF FACTOR VIII PRODUCTS IN CHILDREN AND ADOLESCENTS WITH MODERATE OR SEVERE HAEMOPHILIA A

    Oct 1, 2018, 00:00

  • PCV14 - TREATMENT EFFECT OF PHARMACEUTICAL CARE FOR HYPERTENSIVE PATIENTS IN PRIMARY CARE- A SYSTEMATIC REVIEW AND META-ANALYSES

    Oct 1, 2018, 00:00

  • PND85 - PROPHYLACTIC MIGRAINE MEDICATION USE IN PRIMARY CARE SETTING IN FINLAND

    Oct 1, 2018, 00:00

  • PRM193 - FROM INDIVIDUAL PATIENT TO POPULATION PREFERENCES- MULTINOMIAL LOGIT MODEL VS DIRICHLET DISTRIBUTION

    Oct 1, 2018, 00:00

  • PCN21 - COMPARATIVE EFFICACY OF NIVOLUMAB±IPILIMUMAB VERSUS STANDARD OF CARE (SOC) FOR THIRD-LINE (3L) PATIENTS WITH RECURRENT SMALL CELL LUNG CANCER (SCLC) USING POPULATION-ADJUSTED INDIRECT COMPARISON

    Oct 1, 2018, 00:00

  • PSY121 - RELATIVE VALUE ASSESSMENT OF TREATMENTS FOR RARE DISEASES

    Oct 1, 2018, 00:00

  • PDB38 - BUDGET IMPACT ANALYSIS OF BENAGLUTIDE INJECTION IN THE TREATMENT OF TYPE 2 DIABETES IN CHINA

    Oct 1, 2018, 00:00

  • PSY58 - BUDGET IMPACT ANALYSIS OF EMICIZUMAB IN PEDIATRIC HEMOPHILIA A PATIENTS WITH INHIBITORS IN THE MINISTRY OF HEALTH (MOH), KINGDOM OF SAUDI ARABIA

    Oct 1, 2018, 00:00

  • PHP360 - THE EFFECT OF EUNETHTA ASSESSMENTS ON NATIONAL HTA DECISION MAKING

    Oct 1, 2018, 00:00

  • PSY222 - HEALTH RELATED QUALITY OF LIFE (HRQOL) IN MULTIPLE MYELOMA (MM) PATIENTS IN BULGARIA

    Oct 1, 2018, 00:00

  • PRM78 - TECHNIQUES FOR PREVENTION AND DETECTION OF FRAUD IN RANDOMISED CONTROLLED TRIALS BASED ON ROUTINELY COLLECTED ELECTRONIC HEALTH RECORDS

    Oct 1, 2018, 00:00

  • PSS32 - COST-EFFECTIVENESS OF BRODALUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE

    Oct 1, 2018, 00:00

  • PCV43 - BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF A SINGLE-PILL COMBINATION OF ATORVASTATIN, PERINDOPRIL AND AMLODIPINE IN THE GREEK SETTING

    Oct 1, 2018, 00:00

  • PRM238 - A SIMULATION STUDY ASSESSING THE USE OF PLAUSIBLY VAGUE PRIOR DISTRIBUTIONS IN A BAYESIAN META-ANALYSIS

    Oct 1, 2018, 00:00

  • PSS1 - SYSTEMATIC REVIEWS OF OPHTHALMIC ADVERSE DRUG REACTIONS PUBLISHED IN OPHTHALMOLOGY JOURNALS- A METHODOLOGICAL ASSESSMENT

    Oct 1, 2018, 00:00

  • PRM226 - DEVELOPMENT OF A METHOD FOR A STAR-SHAPED NETWORK META-ANALYSIS UNDER UNIDENTIFIABLE CONSISTENCY ASSUMPTION

    Oct 1, 2018, 00:00

  • PCP39 - INNOVATION IN IDENTIFYING BARRIERS TO ACCESS AND IMPROVING THE QUALITY OF CANCER CARE AND TREATMENT FOR VULNERABLE AREAS PEOPLE, ARGENTINA 2017

    Oct 1, 2018, 00:00

  • PHP16 - CHANGE IN THE QUANTITY OF ONE-DAY SURGERY INTERVENTIONS BETWEEN 1997-2017 IN HUNGARY

    Oct 1, 2018, 00:00

  • PMD69 - SYSTEMATIC REVIEW AND ECONOMIC ANALYSIS OF ANTISEPTIC BARRIER CAPS IN PATIENTS WITH CENTRAL OR PERIPHERAL LINE CATHETERS

    Oct 1, 2018, 00:00

  • PCN111 - COST ESTIMATE OF IMMUNE-RELATED ADVERSE REACTIONS ASSOCIATED WITH INNOVATIVE TREATMENTS OF METASTATIC MELANOMA

    Oct 1, 2018, 00:00

  • PCN169 - A FLEXIBLE OPEN-SOURCE COST-EFFECTIVENESS MODEL FOR METASTATIC EGFR+ NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PCN267 - HEALTHCARE UTILIZATION AND ECONOMIC BURDEN ON PATIENTS WITH BLADDER CANCER IN THE US DEPARTMENT OF DEFENSE POPULATION

    Oct 1, 2018, 00:00

  • PHP133 - TOWARDS IMPLEMENTING MEDICATION THERAPY MANAGEMENT SERVICE IN MALAYSIA- PERCEPTIONS AND CHALLENGES

    Oct 1, 2018, 00:00

  • PUK2 - PREDICTORS FOR BLOOD PRESSURE CONTROL AMONG POST DIALYSIS HYPERTENSIVE PATIENTS WHEN TREATED WITH AND WITHOUT RAAS INHIBITOR

    Oct 1, 2018, 00:00

  • PCN282 - CANCER DRUGS FUND (CDF) IN THE UNITED KINGDOM- A 2-YEAR ANALYSIS

    Oct 1, 2018, 00:00

  • PSY61 - BARIATRIC SURGERY AND COSTS ASSOCIATED WITH HEALTHCARE USE AT TWO YEARS' FOLLOW-UP

    Oct 1, 2018, 00:00

  • PMU59 - ARE THERE ANY IMPLICIT GUIDELINES FOR INCLUDING ADVERSE EVENTS IN COST-EFFECTIVENESS MODELS INTENDED FOR FRENCH HEALTH AUTHORITIES? AN ANALYSIS OF EFFICIENCY OPINIONS

    Oct 1, 2018, 00:00

  • PCN241 - OLAPARIB USE AND TREATMENT OUTCOMES IN SWEDISH PATIENTS TREATED DURING THE FIRST THREE YEARS FOLLOWING REGULATORY APPROVAL

    Oct 1, 2018, 00:00

  • PHP352 - SUCCESS FACTORS FOR THE IMPLEMENTATION OF MARKET ACCESS AGREEMENTS IN EMERGING MIDDLE-INCOME MARKETS IN PREPARATION FOR OUTCOMES BASED CONCEPTS

    Oct 1, 2018, 00:00

  • PIN65 - BUDGET IMPACT ANALYSIS OF THE FIXED DOSE COMBINATION PHOSPHAZIDE/LAMIVUDINE ANTIRETROVIRAL DRUG FOR HIV TREATMENT IN RUSSA

    Oct 1, 2018, 00:00

  • PMD53 - REMOVABLE DINOPROSTONE VAGINAL DELIVERY SYSTEM- COST-CONSEQUENCES MODEL FOR CENTRAL AND EASTERN EUROPE COUNTRIES

    Oct 1, 2018, 00:00

  • PIN43 - A COST-EFFECTIVENESS ANALYSIS OF REVACCINATING OLDER ADULTS WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO VACCINATING WITH A SINGLE DOSE OF PPV23 IN THE UNITED KINGDOM (UK)

    Oct 1, 2018, 00:00

  • PMD135 - DETERMINING FACTORS FOR DECISION-MAKING IN THE MEDICAL TECHNOLOGIES EVALUATION PROGRAMME

    Oct 1, 2018, 00:00

  • PND71 - A COST MINIMISATION ANALYSIS OF CLADRIBINE TABLETS VERSUS ALTERNATIVE HIGH EFFICACY TREATMENTS FOR RELAPSING MULTIPLE SCLEROSIS (RMS) IN THE UNIED KINGDOM.

    Oct 1, 2018, 00:00

  • PCN358 - SATISFACTION WITH HEALTH CARE ANALYSIS IN CERVIX-UTERI CANCER MEXICAN WOMEN TREATED IN A THIRD LEVEL PUBLIC FACILITY

    Oct 1, 2018, 00:00

  • PHP156 - A SCENARIO ANALYSIS OF THE IMPACT OF TREATMENT SETTING ON HEALTH CARE COST AND TREATMENT OUTCOMES

    Oct 1, 2018, 00:00

  • PHP58 - SPANISH THERAPEUTIC POSITIONING REPORTS- 6-YEAR UPDATE – INCREASING IN FREQUENCY BUT NOT RELEVANCE?

    Oct 1, 2018, 00:00

  • PHP59 - MOVING FROM THE REGULATOR TO THE PAYER AND PRESCRIBER - HOW PHARMA CAN WORK BETTER TO EFFECTIVELY MANAGE EMERGING CHALLENGES TO THE COMMERCIAL SUCCESS OF INNOVATIVE NEW THERAPIES

    Oct 1, 2018, 00:00

  • PMD19 - EFFECTIVENESS OF REAL-TIME POLYMERASE CHAIN REACTION FOR THE DIAGNOSIS AND MONITORING OF ADENOVIRUS- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PHP269 - DESIGN AND EVALUATION OF MALAYSIAN MODEL OF PHARMACEUTICAL PICTOGRAMS

    Oct 1, 2018, 00:00

  • PSY50 - BUDGET-IMPACT ANALYSIS (BIA) OF CHRONIC PAIN SYNDROMES FROM A HEALTHCARE PAYER PERSPECTIVE IN BRAZIL

    Oct 1, 2018, 00:00

  • PSY1 - RISK OF LIVER ENZYME ELEVATION IN AUTOIMMUNE PATIENTS WITH DIFFERENT HEPATITIS B VIRUS INFECTION STATUS RECEIVING BIOLOGIC AGENTS

    Oct 1, 2018, 00:00

  • PIN40 - COST-EFFECTIVENESS OF FIRST-LINE TREATMENT FOR INVASIVE ASPERGILOSIS IN COLOMBIA

    Oct 1, 2018, 00:00

  • PMS30 - COST ANALYSIS FOR DIFFERENT ANTI-RHEUMATOID BIOLOGICAL TREATMENTS AFTER FAILURE OF CONVENTIONAL DMARDS IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN THE KINGDOM OF SAUDI ARABIA

    Oct 1, 2018, 00:00

  • RM3 - IS PATIENT CHOICE PREDICTABLE? THE IMPACT OF DISCRETE CHOICE EXPERIMENT DESIGNS AND MODELS

    Oct 1, 2018, 00:00

  • PIH18 - DIRECT COST OF UNINTENDED PREGNANCIES IN JAPAN- ESTIMATING POTENTIAL IMPACTS WITH INCREASED USE OF MODERN CONTRACEPTIVES

    Oct 1, 2018, 00:00

  • PIH38 - PREVALENCE OF PELVIC FLOOR DISORDERS AMONG WOMEN IN EASTERN REGION OF NEPAL

    Oct 1, 2018, 00:00

  • PSY165 - PRICE DIFFERENCES FOR ORPHAN DRUGS ACROSS THE EU-5 COUNTRIES- A COMPARATIVE ASSESSMENT

    Oct 1, 2018, 00:00

  • PCN65 - LONG- TERM SURVIVAL AMONG PATIENTS WITH HIGH-GRADE GLIOMA TREATED WITH NIMOTUZUMAB

    Oct 1, 2018, 00:00

  • PIN125 - A SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITIES FOR HPV-RELATED DISEASES

    Oct 1, 2018, 00:00

  • PMD50 - MAGNETIC RESONANCE-GUIDED FOCUSSED ULTRASOUND VERSUS DEEP BRAIN STIMULATION IN MEDICALLY-REFRACTORY ESSENTIAL TREMOR- A COST-CONSEQUENCE ANALYSIS IN THE UK SETTING

    Oct 1, 2018, 00:00

  • PGI31 - PATTERNS OF ANTI-TNF ADOPTION AND DIFFUSION- REAL WORLD EVIDENCE FROM A 12-YEAR COHORT OF CROHN'S DISEASE AND ULCERATIVE COLITIS PATIENTS TREATED IN TERTIARY REFERAL MEDICAL CENTERS IN ISRAEL

    Oct 1, 2018, 00:00

  • PSY202 - THE OCCUPATIONAL HAZARDS OF MEASURING RISK TOLERANCE- CONVERGENT VALIDITY IN PREFERENCE ELICITATION.

    Oct 1, 2018, 00:00

  • PCV112 - PATTERN OF USE OF ANTIHYPERTENSIVE DRUGS IN TWO EUROPEAN COUNTRIES- COMPARISON OF THE INDEX THERAPIES AND PERSISTENCE

    Oct 1, 2018, 00:00

  • PCP5 - THE ECOLOGICAL AND SOCIAL COSTS AND BENEFITS OF INTERVENTIONS – USING THE PRODUCT CARBON FOOTPRINT IN VALUE ASSESSMENT

    Oct 1, 2018, 00:00

  • PIN9 - NOVEL APPROACH FOR INFLUENZA VACCINATION- APPLICATION OF AN EMERGING TECHNOLOGIES EVALUATION STRATEGY

    Oct 1, 2018, 00:00

  • PMD66 - COMPARING THE LONG-TERM IMPACT ON HEALTHCARE RESOURCES AND COSTS DUE TO SINGLE-PIECE ACRYLIC INTRAOCULAR LENS (IOLS) IMPLANTATION DURING CATARACT SURGERY- A COST-CONSEQUENCE ANALYSIS FROM UK HEALTHCARE SYSTEM PERSPECTIVE

    Oct 1, 2018, 00:00

  • PMS43 - AN ECONOMIC VALUE FRAMEWORK TO ASSESS THE COST EFFECTIVENESS OF FRACTURE PREVENTION TREATMENTS IN PATIENTS WITH OSTEOPOROSIS AT IMMINENT RISK OF FRACTURE

    Oct 1, 2018, 00:00

  • PRM160 - IMPACT OF POST-PROGRESSION OLARATUMAB (OLARA) MONOTHERAPY FOLLOWING DOXORUBICIN (DOX) MONOTHERAPY ON OVERALL SURVIVAL (OS).

    Oct 1, 2018, 00:00

  • PHP265 - LANDSCAPE ASSESSMENT OF A MENA HEALTHCARE DATABASE FOR USE IN HEALTH ECONOMICS MODELING

    Oct 1, 2018, 00:00

  • PSS72 - FAMILY PSO- IMPACT OF PSORIASIS ON THE PARTNER

    Oct 1, 2018, 00:00

  • PCN268 - TREATMENTS AND HEALTH CARE UTILISATION (HCU) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) FOLLOWING INITIAL PLATINUM THERAPY IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PDB121 - QUALITY OF LIFE AND UTILITY VALUES FOR COST-EFFECTIVENESS MODELING IN JAPANESE PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PCN279 - A REVIEW OF RECOMMENDATIONS FOR INCLUSION AND DATA COLLECTION WITHIN THE CDF FRAMEWORK

    Oct 1, 2018, 00:00

  • PSY214 - PHYSICAL ACTIVITY AND QUALITY OF LIFE OUTCOMES IN MULTIPLE MYELOMA PATIENTS- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PIN33 - A DYNAMIC TRANSMISSION MODEL TO ESTIMATE THE PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF TRIVALENT INFLUENZA VACCINE HIGH DOSE FOR THE ELDERLY POPULATION IN ENGLAND AND WALES

    Oct 1, 2018, 00:00

  • AC1 - OUTCOME OF NEW DRUG NEGOTIATION PROCESS IN ITALY- APPROVAL CONDITIONS (2015-2018)

    Oct 1, 2018, 00:00

  • PCV116 - DISCONTINUATION AND HEALTH CARE RESOURCE UTILISATION IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS TREATED WITH APIXABAN OR WARFARIN IN ENGLAND

    Oct 1, 2018, 00:00

  • CV2 - IMPACT OF ATRIAL FIBRILLATION (AF) AWARENESS CAMPAIGNS ON RATES OF AF RELATED CONSULTATIONS IN UK PRIMARY CARE- INTERRUPTED TIME SERIES ANALYSES.

    Oct 1, 2018, 00:00

  • PSY35 - SYSTEMATIC LITERATURE REVIEW ON THE WORLDWIDE EPIDEMIOLOGY OF METHYLMALONIC ACIDEMIA WITH A FOCUS ON METHYLMALONYL-COA MUTASE DEFICIENCY

    Oct 1, 2018, 00:00

  • PSY191 - HEALTH STATE UTILITIES ASSOCIATED WITH TREATMENT FOR TRANSFUSION DEPENDENT B-THALASSEMIA

    Oct 1, 2018, 00:00

  • PMD103 - COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF TREATING LEG ULCERS WITH URGOSTART COMPARED TO A NEUTRAL DRESSING.

    Oct 1, 2018, 00:00

  • PRM61 - LIMITATIONS AND EXPECTED CHALLENGES OF CAR-T ECONOMIC EVALUATION

    Oct 1, 2018, 00:00

  • PRS27 - ECONOMIC BURDEN OF IDIOPATHIC PULMONARY FIBROSIS (IPF) IN CHINA

    Oct 1, 2018, 00:00

  • PCV74 - COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN IN SPANISH PATIENTS AT MODERATE, HIGH, AND VERY HIGH CARDIOVASCULAR RISK

    Oct 1, 2018, 00:00

  • PCN373 - UNDERSTANDING PATIENT PERSPECTIVES OF RENAL CELL CARCINOMA USING SOCIAL MEDIA- A QUALITATIVE ANALYSIS

    Oct 1, 2018, 00:00

  • PMS27 - SECUKINUMAB VERSUS ADALIMUMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS- A COST PER RESPONDER ANALYSIS AMONG 48 WEEKS FROM A TUNISIAN PERSPECTIVE.

    Oct 1, 2018, 00:00

  • PCV120 - INDICATORS OF PRESCRIPTIVE APPROPRIATENESS AS A LEVER FOR PHARMACEUTICAL SUSTAINABILITY - THE CASE OF LOW MOLECULAR WEIGHT HEPARINS

    Oct 1, 2018, 00:00

  • PHP165 - THE LONG-TERM CHANGE OF MEDICAL SERVICE PRICE- AN INTERNATIONAL COMPARISON OF SELECTED COUNTRIES

    Oct 1, 2018, 00:00

  • PHP291 - SHAPING THE FUTURE OF EUROPEAN HEALTH TECHNOLOGY ASSESSMENTS- EXPERIENCES OF THREE PHARMACEUTICAL JOINT RAPID RELATIVE EFFECTIVENESS ASSESSMENTS

    Oct 1, 2018, 00:00

  • PSY99 - COST-EFFECTIVENESS OF TOCILIZUMAB + PREDNISOLONE COMPARED TO STANDARD OF CARE WITH PREDNISOLONE ALONE IN PATIENTS WITH GIANT CELL ARTERITIS (GCA) IN TURKEY

    Oct 1, 2018, 00:00

  • PCN244 - REAL-WORLD EVIDENCE ON THE UTILISATION OF REGORAFENIB IN IRELAND

    Oct 1, 2018, 00:00

  • PMU106 - CHOOSING VIDEO INSTEAD OF IN-CLINIC CONSULTATIONS IN PRIMARY CARE- DISCRETE CHOICE EXPERIMENT AMONG KEY STAKEHOLDERS- PATIENTS, PRIMARY CARE PRACTITIONERS AND POLICY MAKERS

    Oct 1, 2018, 00:00

  • PMS29 - SECUKINUMAB VERSUS ADALIMUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS- A COST PER RESPONDER ANALYSIS AMONG 52 WEEKS FROM A TUNISIAN PERSPECTIVE.

    Oct 1, 2018, 00:00

  • PSY181 - 2018 UPDATE OF HEALTH TECHNOLOGY ASSESSMENT DECISIONS FOR NOVEL PSORIASIS AND PSORIATIC ARTHRITIS AGENTS- RESULTS, RATIONALE, AND TRENDS

    Oct 1, 2018, 00:00

  • CV1 - A COST-EFFECTIVENESS ANALYSIS OF MULITI-GENE PHARMACOGENETIC TESTING IN ACUTE CORONARY SYNDROME PATIENTS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION

    Oct 1, 2018, 00:00

  • PRM276 - METHODOLOGICAL ISSUES OF DRUG PRICE COMPARISON STUDIES- WHAT IMPROVEMENT IN QUALITY?

    Oct 1, 2018, 00:00

  • PSS5 - VISION-RELATED QUALITY OF LIFE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH INTRAVITREAL AFLIBERCEPT- THE AQUA STUDY

    Oct 1, 2018, 00:00

  • PUK33 - COMPARISON OF TREATMENT PATTERN IN UROLITHIASIS - A POPULATION STUDY USING KOREAN HEALTH INSURANCE REVIEW AND ASSESSMENT SERVICE DATABASE

    Oct 1, 2018, 00:00

  • PRM197 - RESPONDER DEFINITION OF THE MULTIPLE SCLEROSIS IMPACT SCALE (MSIS)-29 V2 AMONG PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS

    Oct 1, 2018, 00:00

  • PCN195 - COST-UTILITY ANALYSIS OF THE GERMLINE BRCA TESTING IN WOMEN WITH EPITHELIAL OVARIAN CANCER WITHOUT FAMILY HISTORY IN SPAIN

    Oct 1, 2018, 00:00

  • PUK20 - COST-UTILITY ANALYSIS OF EXTRACORPOREAL LITHOTRIPSY VERSUS URETERORENOSCOPY-HOLMIUM LASER FOR TREATMENT OF URINARY STONES 20 MM.

    Oct 1, 2018, 00:00

  • PSY156 - QUIDS IN? – A REVIEW OF WHETHER POTENTIAL BLOCKBUSTER SAVINGS FROM BIOSIMILAR ADALIMUMAB SHOULD BE REINVESTED IN OTHER DISEASE AREAS?

    Oct 1, 2018, 00:00

  • PMD117 - POINT-OF-CARE TESTING IN PRIMARY CARE- A SYSTEMATIC REVIEW OF TEST EVALUATIONS AND AVAILABLE EVIDENCE

    Oct 1, 2018, 00:00

  • PND76 - THE ECONOMIC CONSEQUENCES OF BENEFITS OF DELAYED-RELEASE DIMETHYL FUMARATE TREATMENT VERSUS BETA INTERFERONS AND GLATIRAMER ACETATE ON ABILITY TO WORK OF MULTIPLE SCLEROSIS PATIENTS IN ITALY

    Oct 1, 2018, 00:00

  • PND131 - PATIENT PREFERENCES FOR DIFFERENT MODES AND FREQUENCY OF ADMINISTRATION OF MULTIPLE SCLEROSIS DISEASE MODIFYING THERAPIES

    Oct 1, 2018, 00:00

  • PCN321 - COMPARISON OF RECOMMENDATIONS FOR CANCER DRUGS CARRIED OUT BY THREE HTA BODIES (2015-2018)- NICE TECHNOLOGY APPRAISALS, GERMAN FEDERAL JOINT COMMITTEE AND SPANISH THERAPEUTIC POSITIONING REPORT

    Oct 1, 2018, 00:00

  • PIN61 - COST-EFFECTIVENESS OF ONCE-DAILY DARUNAVIR CONTAINING SINGLE-TABLET REGIMEN (D/C/F/TAF) COMPARED WITH OTHER MULTI-TABLET REGIMENS CONTAINING BOOSTED PROTEASE INHIBITORS (BPIS)

    Oct 1, 2018, 00:00

  • PDB95 - REAL WORLD EVIDENCE ON TYPE 2 DIABETES- IDENTIFICATION AND CHARACTERIZATION OF NON-INSULIN TREATED PATIENTS WHO FULFIL CONDITIONS FOR THAT TREATMENT

    Oct 1, 2018, 00:00

  • Accuracy of Linking VR-12 and PROMIS Global Health Scores in Clinical Practice

    Oct 1, 2018, 00:00

  • PMU21 - ROLE OF PHARMACISTS FROM RESEARCH TO HEALTHCARE- AN IGNORE PARADIGM IN LOWER INCOME COUNTRY COUNTRY

    Oct 1, 2018, 00:00

  • PMH44 - CANADIAN ECONOMIC IMPACT OF IMPROVED WORKPLACE PRODUCTIVITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH VORTIOXETINE

    Oct 1, 2018, 00:00

  • PRM64 - THE NEED FOR INNOVATIVE SURVIVAL MODELLING APPROACHES IN HEALTH TECHNOLOGY ASSESSMENTS (HTA) OF EARLY-STAGE ONCOLOGY INDICATIONS

    Oct 1, 2018, 00:00

  • PMU82 - SOCIOECONOMIC AND HEALTH-RELATED FACTORS ASSOCIATED WITH ADHERENCE TO CHRONIC MEDICATION IN GREECE

    Oct 1, 2018, 00:00

  • PCN363 - A BEST–WORST SCALING SURVEY OF PREFERENCES OF CURRENT, PAST AND NEVER SMOKERS FOR ADVERSE EFFECTS OF SMOKING IN JAPAN

    Oct 1, 2018, 00:00

  • PCV47 - PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS

    Oct 1, 2018, 00:00

  • PMD42 - ECONOMIC IMPACT OF LAPAROSCOPIC VS OPEN SURGERY FOR COLORECTAL CANCER- A BUDGET IMPACT ANALYSIS IN ITALY

    Oct 1, 2018, 00:00

  • PIN130 - QUALITY OF LIFE OF ADULT PATIENTS UNDERWENT POLIOMYELITIS INFECTION DURING CHILDHOOD

    Oct 1, 2018, 00:00

  • PCN127 - DIRECT HEALTHCARE COSTS BY TREATMENT AMONG PATIENTS WITH MERKEL CELL CARCINOMA (MCC) IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • Estimating a Dutch Value Set for the Pediatric Preference-Based CHU9D Using a Discrete Choice Experiment with Duration

    Oct 1, 2018, 00:00

  • PRM136 - A PILOT OF ONLINE SURVEY SOFTWARE FOR EXPERT ELICITATION AT NICE

    Oct 1, 2018, 00:00

  • PMD34 - BUDGET IMPACT ANALYSIS (BIA) OF EMPLOYING A FEMALE EXTERNAL CATHETER (FEC) TO ASSIST WITH URINE OUTPUT MANAGEMENT (UOM) IN THE HOSPITAL SETTING

    Oct 1, 2018, 00:00

  • PSY9 - REAL-WORLD EPIDEMIOLOGY, TREATMENT PATTERNS AND SURVIVAL OF MULTIPLE MYELOMA PATIENTS IN A LARGE NATIONWIDE HEALTH PLAN

    Oct 1, 2018, 00:00

  • PDB86 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIA

    Oct 1, 2018, 00:00

  • PMD28 - VAGUS NERVE STIMULATION FOR TREATMENT-RESISTANT DEPRESSION- A BUDGET IMPACT ANALYSIS IN ENGLAND

    Oct 1, 2018, 00:00

  • PRS6 - THE CLINICAL EFFECTIVENESS OF PROPHYLACTIC VERSUS SELECTIVE USE OF SURFACTANT IN PRETERM INFANTS- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2018, 00:00

  • PMU76 - PATIENT SATISFACTION FROM INSTRUCTIONS OF COLONOSCOPY PREPARATION AND COST ASSESSMENT OF INADEQUATE BOWEL PREPARATION

    Oct 1, 2018, 00:00

  • PHP93 - THE IMPACT OF SUPPLY CHAIN MARGINS AND VAT ON THE PRICES OF MEDICINES IN BULGARIA AND GREECE

    Oct 1, 2018, 00:00

  • PCV141 - MEDICATION ADHERENCE AND POTENTIAL DETERMINANTS FOR NON-ADHERENCE IN YOUNG AND MALE PATIENTS AT CVD RISK IN KOREA

    Oct 1, 2018, 00:00

  • PMD22 - THE EFFECTIVENESS OF ELECTRONIC LARYNX FOR SPEECH REHABILITATION OF LARINGECTOMIZED PATIENTS- A REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • PRS12 - DEVELOPMENT AND VALIDATION OF AN ALGORITHM IDENTIFYING CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) IN HOSPITAL DISCHARGE DATABASES

    Oct 1, 2018, 00:00

  • PGI10 - COMPARATIVE EFFECTIVENESS OF PAN-GENOTYPIC THERAPIES FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C VIRUS INFECTION IN BULGARIA

    Oct 1, 2018, 00:00

  • PDB137 - COMPARISON OF ORAL ANTIDIABETIC DRUGS AS ADD-ON TREATMENTS IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON METFORMIN- A NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PMU31 - A REVIEW OF MANAGED ACCESS AGREEMENTS (MAAS) AND PATIENT ACCESS SCHEMES (PASS) IN ENGLAND

    Oct 1, 2018, 00:00

  • PDB104 - IMPACT OF DAPAGLIFLOZIN ON REDUCING ECONOMIC BURDEN OF DIABETES IN EGYPT

    Oct 1, 2018, 00:00

  • PRM55 - A NEW ANALYSIS METHODOLOGY TO FIND ATYPICAL COST PROFILES IN PATIENTS LIVING WITH HIV FROM A NATIONAL CLAIM INSURANCE DATA (SNIIRAM)

    Oct 1, 2018, 00:00

  • PCN139 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHO ARE INELIGIBLE FOR CISPLATIN-CONTAINING CHEMOTHERAPY IN ENGLAND

    Oct 1, 2018, 00:00

  • PCN204 - A SYSTEMATIC REVIEW OF BARRIERS AND FACILITATORS TO PARTICIPATION IN SHARED DECISION MAKING IN CANCER CARE- AN INTERNATIONAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCN379 - QUANTITATIVE COMPARISON OF THE INFLUENCE OF OPEN LABEL TRIAL DESIGN ON PATIENT REPORTED OUTCOME RESPONSES – A METASTATIC MELANOMA CASE STUDY.

    Oct 1, 2018, 00:00

  • PUK31 - THE BURDEN ASSOCIATED WITH IMMUNOGLOBULIN A NEPHROPATHY(IGAN)

    Oct 1, 2018, 00:00

  • PND133 - LIVING WITH MIGRAINE- THE IMPACT ON BRAZILIAN PATIENTS LIVES FROM MY MIGRAINE VOICE SURVEY

    Oct 1, 2018, 00:00

  • PRM117 - MULTI-COMPARATOR ICERS IN COST-EFFECTIVENESS ANALYSIS TO ACCOUNT FOR CHANGES IN CLINICAL PRACTICE AFTER THE INTRODUCTION OF A NEW TECHNOLOGY

    Oct 1, 2018, 00:00

  • PCP42 - ECONOMIC EVALUATION OF INTELLIGENT ROLLATORS – ESTIMATING THEIR BENEFITS

    Oct 1, 2018, 00:00

  • PSS15 - BUDGET IMPACT ANALYSIS OF APREMILAST IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE

    Oct 1, 2018, 00:00

  • PDB75 - COST-EFFECTIVENESS OF TREATING PATIENTS WITH TYPE 2 DIABETES POORLY CONTROLLED ON BASAL INSULIN WITH FIXED-RATIO COMBINATIONS OF BASAL INSULIN AND GLP-1 RECEPTOR AGONISTS IN DENMARK- IDEGLIRA VERSUS IGLARLIXI

    Oct 1, 2018, 00:00

  • PIN127 - HETEROGENEOUS PREFERENCES FOR HIV/AIDS COUNSELING AND TESTING AMONG TWO HIGH RISK POPULATIONS IN NORTHERN TANZANIA - RESULTS FROM A DISCRETE CHOICE EXPERIMENT

    Oct 1, 2018, 00:00

  • PCN353 - CONSTRUCT VALIDITY OF EQ-5D-3L IN NON-MELANOMA SKIN CANCER (NMSC)

    Oct 1, 2018, 00:00

  • PND55 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY- COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY ...

    Oct 1, 2018, 00:00

  • PSY186 - CREATING AND MAINTAINING THE BULGARIAN CYSTIC FIBROSIS REGISTRY – NOT REALLY A MISSION IMPOSSIBLE

    Oct 1, 2018, 00:00

  • PRS94 - THE PARENTAL BURDEN OF CARING FOR A CHILD WITH PEANUT ALLERGY IN THE UK

    Oct 1, 2018, 00:00

  • PSY54 - BUDGET IMPACT ANALYSIS OF NINTEDANIB IN IDIOPATHIC PULMONARY FIBROSIS IN TURKEY

    Oct 1, 2018, 00:00

  • PDB48 - ANNUAL COST OF ILLNESS OF ISCHEMIC STROKE IN TYPE 2 DIABETIC PATIENTS IN TURKEY

    Oct 1, 2018, 00:00

  • PHP305 - CONSIDERING CHILDREN ALONGSIDE ADULTS IN NICE TECHNOLOGY APPRAISALS AND HIGHLY SPECIALISED TECHNOLOGIES EVALUATIONS

    Oct 1, 2018, 00:00

  • PCN198 - AN ECONOMIC SYSTEMATIC LITERATURE REVIEW (SLR) FOR ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+) NON-SMALL-CELL LUNG CANCER (NSCLC)

    Oct 1, 2018, 00:00

  • PHP12 - PATIENTS’ RELATED ISSUES ARISING FROM TARGET PRODUCT PROFILE, PRODUCT DEVELOPMENT PLAN AND IN THE DESIGN OF CLINICAL TRIALS

    Oct 1, 2018, 00:00

  • PHP313 - ANALYSIS OF THE ANALYTICAL AND METHODOLOGICAL FRAMEWORK OF THE HEALTH ECONOMIC EVALUATION ASSESSMENTS DELIVERED IN FRANCE

    Oct 1, 2018, 00:00

  • PMS118 - QUALITY OF LIFE OF DUPUYTREN’S DISEASE PATIENTS TREATED WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM- A PROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PHP181 - HEALTH TECHNOLOGY ASSESSMENT OF ONCOLOGY THERAPIES IN SPAIN AND ITALY- KEY METRICS AND CONSIDERATIONS

    Oct 1, 2018, 00:00

  • PHP274 - ITALY’S NEW PHARMACEUTICAL INNOVATION RANKING SYSTEM- KEY CRITERIA FOR SUCCESSFULLY ACHIEVING INNOVATIVE STATUS

    Oct 1, 2018, 00:00

  • PDB50 - COST OF HYPOGLYCAEMIA IN BOSNIA AND HERZEGOVINA

    Oct 1, 2018, 00:00

  • PCP2 - IS DIGITAL TECHNOLOGY BRINGING THE ADOPTERS CLOSER TO THE DECISION-MAKERS- A COMPARATIVE ASSESSMENT ACROSS FIVE EUROPEAN MARKETS.

    Oct 1, 2018, 00:00

  • PCN385 - QUALITY OF LIFE OF PATIENTS LIVING WITH METASTATIC COLORECTAL CANCER (MCRC)- EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER (EORTC) QUESTIONNAIRE RESULTS FROM A REAL WORLD EUROPEAN SURVEY

    Oct 1, 2018, 00:00

  • PCP62 - MARKET ACCESS UNDER AGILE CIRCUMSTANCES

    Oct 1, 2018, 00:00

  • PMU39 - PRICE ASSESSMENT OF ESSENTIAL GENERICS IN THE CITY OF YEREVAN

    Oct 1, 2018, 00:00

  • PCV114 - PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH PRESCRIPTION OF NOVEL ORAL COAGULANTS IN A LARGE HEALTHCARE SERVICE PROVIDER IN ISRAEL

    Oct 1, 2018, 00:00

  • PND1 - REVIEW OF THE LISTED SIDE EFFECTS OF MYASTHENIA GRAVIS TREATMENTS VERSUS THOSE RECORDED IN PUBLICATIONS

    Oct 1, 2018, 00:00

  • PIN119 - THERAPEUTIC SEQUENCES FOR THE TREATMENT OF PEOPLE LIVING WITH HIV TYPE 1 IN PORTUGAL

    Oct 1, 2018, 00:00

  • PDB83 - A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS IN NON-INSULIN ANTIDIABETIC TREATMENTS FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PDB24 - BASELINE CHARACTERISTICS OF GERMAN DIABETES MELLITUS TYPE-2 PATIENTS WHO INITIATED INSULIN USAGE- A CLAIMS DATA ANALYSIS

    Oct 1, 2018, 00:00

  • PHP277 - HOW DO BELLWETHER HTA AGENCIES EVALUATE BIOSIMILARS?

    Oct 1, 2018, 00:00

  • PHP44 - EXPLORING THE KNOWLEDGE AND PERCEPTION OF GENERIC MEDICINE USE AMONG COMMUNITY PHARMACISTS IN SAUDI ARABIA

    Oct 1, 2018, 00:00

  • MD3 - FROM DRUG-DELIVERY DEVICE TO DISEASE MANAGEMENT TOOL- A STUDY OF PATIENT PREFERENCES FOR ENHANCED FEATURES IN NEXT GENERATION SELF-INJECTION DEVICES

    Oct 1, 2018, 00:00

  • PMS90 - A BONE RESORPTION MARKER TO MONITOR DRUG PROFILE IN PATIENTS WITH OSTEOPOROTIC FRACTURES

    Oct 1, 2018, 00:00

  • PMU22 - ANTICHOLINERGIC BURDEN IN OLDER PATIENTS- PHARMACIST INTERVENTION

    Oct 1, 2018, 00:00

  • PRS5 - IDENTIFICATION AND ESTIMATION OF THE PREVALENCE OF ACUTE SEVERE ASTHMA IN FRANCE USING THE EGB CLAIM DATABASE

    Oct 1, 2018, 00:00

  • PUK8 - EVALUATION OF PRESCRIBING PRACTICES AND DRUG-RELATED PROBLEMS IN CHRONIC KIDNEY DISEASE PATIENTS- A PROSPECTIVE OBSERVATIONAL STUDY

    Oct 1, 2018, 00:00

  • PIN118 - KNOWLEDGE, ATTITUDE AND PRACTICES ABOUT ZIKA VIRUS AMONG PHARMACY STUDENTS IN THE UNITED STATES (US) AND INDIA- A CROSS SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • PCN248 - USE OF CANCER DRUGS IN THE END-OF-LIFE IN MEN DYING OF CASTRATION-RESISTANT PROSTATE CANCER- POPULATION-BASED STUDY

    Oct 1, 2018, 00:00

  • PIN34 - COMPARING THE ESTIMATED PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF PHID-CV AND PCV-13 IN THE ROUTINE IMMUNISATION PROGRAMME IN GAVI-ELIGIBLE COUNTRIES (SUB-SAHARAN AFRICA AND ASIA/OCEANIA)- A MODELLING STUDY

    Oct 1, 2018, 00:00

  • PHP96 - TIME EFFICIENCY IN THE REGULATORY DECISION-MAKING PROCESS OF ORPHAN DRUGS

    Oct 1, 2018, 00:00

  • PHP357 - MAKING SENSE FROM ANTI-SENSE- LESSONS IN TRANSLATING EXPEDITED REGULATORY APPROVAL INTO REIMBURSEMENT AND COMMERCIAL SUCCESS

    Oct 1, 2018, 00:00

  • DS1 - EPIDEMIOLOGY, TREATMENT, AND HEALTH RESOURCE USE OF GOUT PATIENTS IN GERMANY- RESULTS FROM ANALYSIS OF A CLAIMS DATABASE

    Oct 1, 2018, 00:00

  • PCP1 - COMPARISON OF THE GERMAN MIXED PRICE MODEL AND INDICATION-SPECIFIC PRICING FOR MULTI-INDICATION PRODUCTS IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PHP183 - PRICE DIFFERENCE OF MEDICINES DISPENSED IN COMMUNITY PHARMACIES AND IN THE HOSPITAL SECTOR - AN ANALYSIS ON THE MEDICINES FINANCED ON THE BASIS OF HOSPITAL SERVICE TARIFFS

    Oct 1, 2018, 00:00

  • PMD163 - HTA OF ARTIFICIAL URINARY SPHINCTER (AUS) FOR THE TREATMENT OF SEVERE MALE POST-PROSTATECTOMY INCONTINENCE IN ITALY

    Oct 1, 2018, 00:00

  • PMS54 - COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT AS FIRST LINE OF TREATMENT IN COLOMBIAN PATIENTS WITH PSORIATIC ARTHRITIS

    Oct 1, 2018, 00:00

  • PRM133 - ESTIMATED COST SAVINGS FROM DOSE BANDING GUIDANCE- A CASE STUDY USING TREATMENTS FOR STAGE IV MELANOMA

    Oct 1, 2018, 00:00

  • PHP106 - IMPACT OF ACCESS RESTRICTION ON USE OF SHORT-ACTING PRESCRIPTION OPIOIDS IN A US HEALTH PLAN

    Oct 1, 2018, 00:00

  • PHP330 - REAL-WORLD DATA COLLECTION ON MEDICAL DEVICES IN THE ERA OF VALUE-BASED HEALTHCARE- A LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PRM41 - ESTIMATION OF HOSPITAL COST SAVINGS ASSOCIATED WITH HYPOTENSION REDUCTION IN SEPTIC INTENSIVE CARE UNIT PATIENTS IN FRANCE

    Oct 1, 2018, 00:00

  • PND2 - RISK OF PARKINSON’S DISEASE (PD) IN PATIENTS TAKING ADRENERGIC DRUG TREATMENTS

    Oct 1, 2018, 00:00

  • PCN93 - ECONOMIC MODELING FOR THE US OF INTRAVENOUS VS SUBCUTANEOUS RITUXIMAB IN NON-HODGKIN’S LYMPHOMA TREATED WITH R-CHOP

    Oct 1, 2018, 00:00

  • PND41 - HEALTHCARE COSTS OF PATIENTS WITH SPINAL MUSCULAR ATROPHY

    Oct 1, 2018, 00:00

  • PRM47 - UNDERSTANDING KEY VALUE DRIVERS OF A NOVEL TREATMENT IN MANAGEMENT OF FAMILIAL CHYLOMICRONEMIA SYNDROME

    Oct 1, 2018, 00:00

  • PHP358 - TIME-LIMITED G-BA RESOLUTIONS – A TOOL TO APPROPRIATELY MANAGE REIMBURSEMENT OF INNOVATIVE THERAPIES RECEIVING EXPEDITED REGULATORY APPROVAL

    Oct 1, 2018, 00:00

  • PDB27 - CLINICAL INERTIA IN RELATION TO BARRIERS TO PROGRESSION TO INJECTABLE THERAPY IN TYPE 2 DIABETES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMD146 - HEALTH CARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH ASEPTIC LOOSENING AFTER PRIMARY TOTAL KNEE ARTHROPLASTY

    Oct 1, 2018, 00:00

  • PSY149 - IQVIA PATIENT DATA ASSESSMENT- REAL WORLD EVIDENCE IN THE MANAGEMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS

    Oct 1, 2018, 00:00

  • PIN38 - CLINICAL AND ECONOMIC IMPACT OF THE TREATMENT OF CHRONIC HEPATITIS C IN PRISON INMATES IN SPAIN

    Oct 1, 2018, 00:00

  • PSY81 - DIRECT COSTS ASSOCIATED WITH THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RELAPSED OR REFRACTORY IN ARGENTINA

    Oct 1, 2018, 00:00

  • PMU99 - PERCEPTIONS OF THE GREEK POPULATION CONCERNING MEDICINES – A DESCRIPTIVE ANALYSIS

    Oct 1, 2018, 00:00

  • PRM77 - VALIDATION OF COPD ICD10 DIAGNOSTIC CODES IN THE SIDIAP PRIMARY HEALTH CARE RESEARCH DATABASE USING A COMBINATION OF SPIROMETRY MEASURES, SYMPTOMS, DRUG USE, AND FREE TEXT REVIEW.

    Oct 1, 2018, 00:00

  • PIN85 - TENOFOVIR ALAFENAMIDE’S IMPACT ON COMORBIDITIES AMONG PEOPLE LIVING WITH HIV IN PORTUGAL- A SIMULATION STUDY

    Oct 1, 2018, 00:00

  • PDB59 - COST-EFFECTIVENESS OF SWITCHING TO INSULIN DEGLUDEC (IDEG) U100 FROM CURRENTLY AVAILABLE BASAL INSULINS IN BELGIUM BASED ON EVIDENCE FROM REAL-WORLD CLINICAL PRACTICE

    Oct 1, 2018, 00:00

  • PCN332 - REAL-WORLD USAGE OF BORTEZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE (VTD) AS FRONTLINE (FL) TREATMENT IN STEM CELL TRANSPLANT (SCT) ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ACROSS EU5 COUNTRIES

    Oct 1, 2018, 00:00

  • PMD61 - COST EFFECTIVENESS OF DERMABOND PRINEO SKIN CLOSURE SYSTEM IN HIP AND KNEE ARTHROPLASTY IN TURKEY

    Oct 1, 2018, 00:00

  • PCP11 - ORGANISATIONAL MODELS AND OPPORTUNITIES FOR EFFICIENCY MEASURING IN HEALTH CARE

    Oct 1, 2018, 00:00

  • PSS60 - UTILITY ASSESSMENT FOR PEMPHIGUS HEALTH STATES USING VISUAL ANALOGUE SCALE AND TIME TRADE-OFF METHODS

    Oct 1, 2018, 00:00

  • PDB1 - ACUTE RENAL OUTCOMES WITH SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS- REAL WORLD DATA ANALYSIS

    Oct 1, 2018, 00:00

  • PHP100 - UTILIZATIONS AND EXPENDITURES OF TUMOR NECROSIS FACTOR ANTAGONISTS IN MEDICARE PART D- CROSS- SECTIONAL STUDY (2014-2015)

    Oct 1, 2018, 00:00

  • PDB93 - IMPACT OF CARDIOVASCULAR DISEASE ON HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH TYPE 2 DIABETES IN A REAL WORLD SETTING

    Oct 1, 2018, 00:00

  • PMD179 - PATIENTS’ USABILITY OF SIX MOST USED DRY-POWDER INHALERS IN ASTHMA AND COPD

    Oct 1, 2018, 00:00

  • PRM67 - UTILITIES IN ONCOLOGY SUBMISSIONS SUBMITTED TO NICE —APPROACH OF THE MANUFACTURERS

    Oct 1, 2018, 00:00

  • PHP116 - TREND IN OPIOID USE FROM 2001 THROUGH 2013 AMONG ELDERLY US VETERANS

    Oct 1, 2018, 00:00

  • PSS35 - SECUKINUMAB VERSUS USTEKINUMAB FOR THE TREATMENT OF PSORIASIS- A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM150 - TECHNOLOGY DIFFUSION IN HEALTHCARE- INSIGHTS FROM AN AGENT-BASED SIMULATION

    Oct 1, 2018, 00:00

  • PND27 - COST IMPLICATIONS IN THE SELECTION OF FIRST LINE TREATMENT FOR HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PMD83 - CERVICAL CANCER SCREENING IN EUROPE - A SYSTEMATIC REVIEW ON COST EFFECTIVENESS STUDIES WITH SPECIFIC INTEREST ON RISK-ADAPTED STRATEGIES

    Oct 1, 2018, 00:00
  • «
  • 51
  • 52
  • 53
  • 54
  • 55 (current)
  • 56
  • 57
  • 58
  • 59
  • 60
  • »